|
Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Clinical research trials and Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer. Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer clinical trial. Subjects often receive the most expert healthcare possible for their Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer  Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
For Condition: Larynx Cancer,Head and Neck Cancer,Oropharynx Cancer,Hypopharynx Cancer
Status: Recruiting
Sponsor(s): Pharmacyclics ,
Synopsis: The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - At least 18 years of age - Each patient must sign a study-specific informed consent form - Newly diagnosed, locally advanced, non-metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) arising from a primary site in the oropharynx, hypopharynx, or larynx confirmed by evaluation of fine needle aspiration or biopsy samples and MRI - Eligible for curative intent treatment with hyperfractionated radiation and concurrent 5-FU and cisplatin - Karnofsky Performance Status score of at least 60% - Primary tumor at least 4 cm in diameter Exclusion Criteria: Laboratory Values of: - Serum creatinine > 1.8 mg/dL; unless 24-hour urine creatinine clearance is 70 mL/min - Serum total bilirubin > 1.5 times the upper limit of normal - ALT (formerly SGPT) > 1.5 times the upper limit of normal - Alkaline phosphatase > 1.5 times the upper limit of normal - Absolute neutrophil count (ANC) < 1500/L - Platelet count < 100,000/L - 3+ or greater proteinuria on urinalysis and - Squamous Cell Carcinoma of the Head and Neck arising from a primary site in the oral cavity or nasopharynx - Distant metastases - Prior history of cancer at any site treated with radiotherapy and/or chemotherapy - History of SCCHN diagnosed within 5 years of current diagnosis
Total Enrollment: 18
Location and Contact Information:
University of Texas, San Antonio Health Science Center *Recruiting*
San Antonio, Texas,
United States
Recruiting
Duke University Medical Center *Recruiting*
Durham, North Carolina,
United States
Recruiting
Additional Information:
Study ID Numbers: PCYC-0210;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080028
Other Oropharynx Cancer Studies:
1. Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
Related Studies:
Other Oropharynx Cancer Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
Motexafin Gadolinium with Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
|
|
|
|
|
|
|
|
